A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

A recent analysis suggested that only one in four people on antiretroviral treatment take 95% or more of their doses.

ViiV applies for FDA approval of HIV drug fostemsavir

In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.

Gilead’s HIV capsid inhibitor might need dosing only every six months

A recent survey found that pharmacies are insufficiently educating the public about unused opioid and antibiotic disposal.

Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.

The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.